Search

Displaying results 7861 - 7870 of 8970 in total
  1. Drug

    AZD2389

    go.drugbank.com/drugs/DB22104
    Investigational

    NCT06973005: A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants).

  2. Drug

    Cyamemazine

    go.drugbank.com/drugs/DB09000
    Experimental

    Cyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).

  3. Drug

    ATG-101

    go.drugbank.com/drugs/DB17162
    Investigational

    ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors

  4. Drug

    RO7296682

    go.drugbank.com/drugs/DB17531
    Investigational

    RO7296682 is under investigation in clinical trial NCT04642365 (A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors. … RO7296682 is a monoclonal antibody against CD25 (IL-2R alpha) expressed on tumour-infiltrating regulatory T (T<sub>reg</sub>) cells.

    Synonyms: RO 7296682, RO-7296682
  5. Drug

    L-cysteic acid

    go.drugbank.com/drugs/DB03661
    Experimental

    It occurs normally in the outer part of the sheep's fleece, where the wool is exposed to light and weather.

  6. Drug

    Asapiprant

    go.drugbank.com/drugs/DB20492
    Investigational

    Asapiprant is under investigation in clinical trial NCT04705597 (Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That

  7. Drug

    Daleuton

    go.drugbank.com/drugs/DB00154
    InvestigationalNutraceutical

    A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.

  8. Drug

    7MW3711

    go.drugbank.com/drugs/DB19298
    Investigational

    Developed by Mabwell, 7MW3711 is an antibody-drug conjugate targeting B7-H3.[L50918,L50923]

  9. Drug

    PF-07799933

    go.drugbank.com/drugs/DB17489
    Investigational

    PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.

  10. Drug

    Sipagladenant

    go.drugbank.com/drugs/DB17080
    Investigational

    KW-6356 is a selective antagonist of adenosine A2A receptors developed by Kyowa Kirin.[L43822]